{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:57:51Z","timestamp":1784343471675,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Gout results from an innate immune response to monosodium urate (MSU) crystals deposited in joints. Increased very low-density lipoprotein (VLDL) has been associated with gout. The apolipoprotein B (apo B), which is present on VLDL, regulates neutrophil response to MSU crystals and has been positively associated with gout. Furthermore, the gene (<jats:italic>A1CF<\/jats:italic>) encoding the complementation factor for the <jats:italic>APOB<\/jats:italic> mRNA-editing enzyme is associated with urate levels. However, the relationship of apo B and VLDL with gout and hyperuricaemia (HU) is still unclear. Therefore, we tested the association of VLDL and apo B with HU and with gout compared to HU.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>New Zealand European (n\u2009=\u200990) and M\u0101ori and Pacific Island (Polynesian) (n\u2009=\u200990) male gout case and control sample sets were divided into normouricaemia (NU), asymptomatic HU and gout groups. Size exclusion chromatography and enzyme-linked immunosorbant assay was used to measure VLDL and apo B. Multivariate logistic regression was used to assess the risk of gout and HU per unit change in VLDL and apo B.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Increased levels of VLDL triglycerides (Tg) were observed in the gout sample set compared to NU and HU in Europeans (<jats:italic>P<\/jats:italic>\u2009=\u20091.8\u2009\u00d7\u200910<jats:sup>-6<\/jats:sup> and 1\u2009\u00d7\u200910<jats:sup>-3<\/jats:sup>, respectively), but only compared to NU in Polynesians (<jats:italic>P<\/jats:italic>\u2009=\u20090.023). This increase was driven by increased number of VLDL particles in the European participants and by the Tg-enrichment of existing VLDL particles in the Polynesian participants. Each mmol\/L increase in VLDL Tg was significantly associated with gout in the presence of HU in Europeans, with a similar trend in Polynesians (OR\u2009=\u20097.61, <jats:italic>P<\/jats:italic>\u2009=\u20090.011 and 2.84, <jats:italic>P<\/jats:italic>\u2009=\u20090.069, respectively). Each \u03bcmol\/L increase in total apo B trended towards decreased risk of HU (OR\u2009=\u20090.47; <jats:italic>P<\/jats:italic>\u2009=\u20090.062) and, conversely, with increased risk of gout compared to HU (OR\u2009=\u20095.60; <jats:italic>P<\/jats:italic>\u2009=\u20090.004).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Increased VLDL Tg is associated with the risk of gout compared to HU. A genetic approach should be taken to investigate the possibility for causality of VLDL in gout. Apolipoprotein B may have pleiotropic effects in determining HU and gout.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-014-0495-z","type":"journal-article","created":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T02:07:40Z","timestamp":1417226860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout"],"prefix":"10.1186","volume":"16","author":[{"given":"Humaira","family":"Rasheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony R","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,29]]},"reference":[{"key":"495_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.rdc.2014.01.009","volume":"40","author":"TR Merriman","year":"2014","unstructured":"Merriman TR, Choi HK, Dalbeth N: The genetic basis of gout. Rheum Dis Clin North Am. 2014, 40: 279-290. 10.1016\/j.rdc.2014.01.009.","journal-title":"Rheum Dis Clin North Am"},{"key":"495_CR2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","volume":"23","author":"JA Singh","year":"2011","unstructured":"Singh JA, Reddy SG, Kundukulam J: Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011, 23: 192-202.","journal-title":"Curr Opin Rheumatol"},{"key":"495_CR3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/0026-0495(89)90110-8","volume":"38","author":"K Matsubara","year":"1989","unstructured":"Matsubara K, Matsuzawa Y, Jiao S, Takama T, Kubo M, Tarui S: Relationship between hypertriglyceridemia and uric acid production in primary gout. Metabolism. 1989, 38: 698-701. 10.1016\/0026-0495(89)90110-8.","journal-title":"Metabolism"},{"key":"495_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1053\/meta.2001.24930","volume":"50","author":"Z Tsutsumi","year":"2001","unstructured":"Tsutsumi Z, Yamamoto T, Moriwaki Y, Takahashi S, Hada T: Decreased activities of lipoprotein lipase and hepatic triglyceride lipase in patients with gout. Metabolism. 2001, 50: 952-954. 10.1053\/meta.2001.24930.","journal-title":"Metabolism"},{"key":"495_CR5","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1172\/JCI111380","volume":"73","author":"R Terkeltaub","year":"1984","unstructured":"Terkeltaub R, Curtiss LK, Tenner AJ, Ginsberg MH: Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. J Clin Invest. 1984, 73: 1719-1730. 10.1172\/JCI111380.","journal-title":"J Clin Invest"},{"key":"495_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/ard.2003.019695","volume":"64","author":"F Cardona","year":"2005","unstructured":"Cardona F, Tinahones FJ, Collantes E, Escudero A, Garc\u00eda-Fuentes E, Soriguer F: Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout. Ann Rheum Dis. 2005, 64: 85-88. 10.1136\/ard.2003.019695.","journal-title":"Ann Rheum Dis"},{"key":"495_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/rheumatology\/34.10.920","volume":"34","author":"F Tinahones","year":"1995","unstructured":"Tinahones F, Collantes E, C-Soriguer F, Gonzalez-Ruiz A, Pineda M, Anon J, Guijo PS: Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients. Rheumatology. 1995, 34: 920-924. 10.1093\/rheumatology\/34.10.920.","journal-title":"Rheumatology"},{"key":"495_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00270300","volume":"5","author":"A Ulreich","year":"1985","unstructured":"Ulreich A, Kostner G, Pfeiffer K, Sedlmayr P, Rainer F: Serum lipids and lipoproteins in patients with primary gout. Rheumatol Int. 1985, 5: 73-77. 10.1007\/BF00270300.","journal-title":"Rheumatol Int"},{"key":"495_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A K\u00f6ttgen","year":"2013","unstructured":"K\u00f6ttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O'Seaghdha CM, Haller T, Yang Q, Tanaka T, Johnson AD, Kutalik Z, Smith AV, Shi J, Struchalin M, Middelberg RP, Brown MJ, Gaffo AL, Pirastu N, Li G, Hayward C, Zemunik T, Huffman J, Yengo L, Zhao JH, Demirkan A, Feitosa MF, Liu X: Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013, 45: 145-154. 10.1038\/ng.2500.","journal-title":"Nat Genet"},{"key":"495_CR10","doi-asserted-by":"crossref","unstructured":"Phipps-Green A, Merriman M, Topless R, Altaf S, Montgomery GW, Franklin C, Jones GT, van Rij AM, White D, Stamp LK, Dalbeth N, Merriman TR: Twenty-eight loci that influence serum urate levels: analysis of association with gout.Ann Rheum Dis 2014. doi: 10.1136\/annrheumdis-2014-205877. [Epub ahead of print],","DOI":"10.1136\/annrheumdis-2014-205877"},{"key":"495_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977, 20: 895-900. 10.1002\/art.1780200320.","journal-title":"Arthritis Rheum"},{"key":"495_CR12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","volume":"41","author":"SM Marcovina","year":"1995","unstructured":"Marcovina SM, Albers JJ, Gabel B, Koschinsky M, Gaur V: Effect of the number of apolipoprotein (a) kringle 4 domains on immunochemical measurements of lipoprotein (a). Clin Chem. 1995, 41: 246-255.","journal-title":"Clin Chem"},{"key":"495_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0009-8981(80)90257-0","volume":"101","author":"G Sanders","year":"1980","unstructured":"Sanders G, Pasman A, Hoek F: Determination of uric acid with uricase and peroxidase. Clin Chim Acta. 1980, 101: 299-303. 10.1016\/0009-8981(80)90257-0.","journal-title":"Clin Chim Acta"},{"key":"495_CR14","unstructured":"Foster-Swanson A, Swartzentruber M, Roberts P, Feld R, Johnson M, Wong S: Reference interval studies of the rate-blanked creatinine\/Jaffe method on BM\/Hitachi systems in six US laboratories.Clin Chem 1994, 40:1057.,"},{"key":"495_CR15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0022-2275(20)33305-8","volume":"39","author":"W Innis-Whitehouse","year":"1998","unstructured":"Innis-Whitehouse W, Li X, Brown WV, Le N-A: An efficient chromatographic system for lipoprotein fractionation using whole plasma. J Lipid Res. 1998, 39: 679-690.","journal-title":"J Lipid Res"},{"key":"495_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.mehy.2010.07.030","volume":"75","author":"P Hu","year":"2010","unstructured":"Hu P, Lu L, Hu B, Qin YH: Recapture of hepatic apolipoprotein B mRNA editing may be a promising strategy to relieve nephrotic dyslipidemia. Med Hypotheses. 2010, 75: 561-563. 10.1016\/j.mehy.2010.07.030.","journal-title":"Med Hypotheses"},{"key":"495_CR17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.27356","volume":"62","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth N, Pool B, Gamble GD, Smith T, Callon KE, McQueen F, Cornish J: Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 2010, 62: 1549-1556. 10.1002\/art.27356.","journal-title":"Arthritis Rheum"},{"key":"495_CR18","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/rheumatology\/keh640","volume":"44","author":"N Dalbeth","year":"2005","unstructured":"Dalbeth N, Haskard D: Mechanisms of inflammation in gout. Rheumatology. 2005, 44: 1090-1096. 10.1093\/rheumatology\/keh640.","journal-title":"Rheumatology"},{"key":"495_CR19","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/art.1780360912","volume":"36","author":"E Ortiz-Bravo","year":"1993","unstructured":"Ortiz-Bravo E, Sieck MS, Ralph Schumacher H: Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum. 1993, 36: 1274-1285. 10.1002\/art.1780360912.","journal-title":"Arthritis Rheum"},{"key":"495_CR20","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/bi00391a044","volume":"26","author":"N Hirose","year":"1987","unstructured":"Hirose N, Blankenship DT, Jackson RL, Cardin AD: Isolation and characterization of four heparin-binding cyanogen bromide peptides of human plasma apolipoprotein B. Biochemistry. 1987, 26: 5505-5512. 10.1021\/bi00391a044.","journal-title":"Biochemistry"},{"key":"495_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10067-014-2620-4","volume":"33","author":"TL Jansen","year":"2014","unstructured":"Jansen TL, Berendsen D, Crisan TO, Cleophas MCP, Janssen MCH, Joosten LAB: New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome. Clin Rheumatol. 2014, 33: 1341-1346. 10.1007\/s10067-014-2620-4.","journal-title":"Clin Rheumatol"},{"key":"495_CR22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0022-2275(20)37210-2","volume":"38","author":"K Hirano","year":"1997","unstructured":"Hirano K, Min J, Funahashi T, Baunoch D, Davidson N: Characterization of the human apobec-1 gene: expression in gastrointestinal tissues determined by alternative splicing with production of a novel truncated peptide. J Lipid Res. 1997, 38: 847-859.","journal-title":"J Lipid Res"},{"key":"495_CR23","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998, 98: 2088-2093. 10.1161\/01.CIR.98.19.2088.","journal-title":"Circulation"},{"key":"495_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2169\/internalmedicine.49.2597","volume":"49","author":"D Uetake","year":"2010","unstructured":"Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, Endou H, Hosoya T: Effect of fenofibrate on uric acid metabolism and urate transporter 1. Internal Med. 2010, 49: 89-94. 10.2169\/internalmedicine.49.2597.","journal-title":"Internal Med"},{"key":"495_CR25","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/j.1552-4604.1980.tb01670.x","volume":"20","author":"JP Desager","year":"1980","unstructured":"Desager JP, Hulhoven R, Harvengt C: Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol. 1980, 20: 560-564. 10.1002\/j.1552-4604.1980.tb01670.x.","journal-title":"J Clin Pharmacol"},{"key":"495_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0026-0495(88)90098-4","volume":"37","author":"M Bastow","year":"1988","unstructured":"Bastow M, Durrington P, Ishola M: Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism. 1988, 37: 217-220. 10.1016\/0026-0495(88)90098-4.","journal-title":"Metabolism"},{"key":"495_CR27","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1136\/annrheumdis-2012-202732","volume":"72","author":"N Dalbeth","year":"2013","unstructured":"Dalbeth N, House ME, Gamble GD, Horne A, Pool B, Purvis L, Stewart A, Merriman M, Cadzow M, Phipps-Green A, Merriman TR: Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis. 2013, 72: 1868-1873. 10.1136\/annrheumdis-2012-202732.","journal-title":"Ann Rheum Dis"},{"key":"495_CR28","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/art.30649","volume":"63","author":"F Perez-Ruiz","year":"2011","unstructured":"Perez-Ruiz F, Herrero-Beites AM, Carmona L: A two-stage approach to the treatment of hyperuricemia in gout: The \u201cdirty dish\u201d hypothesis. Arthritis Rheum. 2011, 63: 4002-4006. 10.1002\/art.30649.","journal-title":"Arthritis Rheum"},{"key":"495_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3904\/kjim.2006.21.2.89","volume":"21","author":"Y-H Lee","year":"2006","unstructured":"Lee Y-H, Lee C-H, Lee J: Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Internal Med. 2006, 21: 89-93. 10.3904\/kjim.2006.21.2.89.","journal-title":"Korean J Internal Med"},{"key":"495_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/ard.62.6.572","volume":"62","author":"S Takahashi","year":"2003","unstructured":"Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M: Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism. Ann Rheum Dis. 2003, 62: 572-575. 10.1136\/ard.62.6.572.","journal-title":"Ann Rheum Dis"},{"key":"495_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","volume":"42","author":"M Feher","year":"2003","unstructured":"Feher M, Hepburn A, Hogarth M, Ball S, Kaye S: Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology. 2003, 42: 321-325. 10.1093\/rheumatology\/keg103.","journal-title":"Rheumatology"},{"key":"495_CR32","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.metabol.2009.04.040","volume":"58","author":"S Otokozawa","year":"2009","unstructured":"Otokozawa S, Ai M, Diffenderfer MR, Asztalos BF, Tanaka A, Lamon-Fava S, Schaefer EJ: Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism. 2009, 58: 1536-1542. 10.1016\/j.metabol.2009.04.040.","journal-title":"Metabolism"},{"key":"495_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","volume":"118","author":"S Mora","year":"2008","unstructured":"Mora S, Rifai N, Buring JE, Ridker PM: Fasting compared with nonfasting lipids and apolipoprotein for predicting incident cardiovascular events. Circulation. 2008, 118: 993-1001. 10.1161\/CIRCULATIONAHA.108.777334.","journal-title":"Circulation"},{"key":"495_CR34","doi-asserted-by":"crossref","unstructured":"Rasheed H, Hughes K, Flynn TJ, Merriman TR: Mendelian randomisation provides no evidence for a causal role of serum urate in increasing serum triglyceride levels.Circ Cardiovasc Genet 2014. doi:10.1161\/CIRCGENETICS.114.000556. [Epub ahead of print],","DOI":"10.1161\/CIRCGENETICS.114.000556"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0495-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-014-0495-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0495-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0495-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:26:16Z","timestamp":1728923176000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-014-0495-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,29]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1186\/s13075-014-0495-z","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,29]]},"assertion":[{"value":"9 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"495"}}